

# Paul J Hoskins

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4568246/publications.pdf>

Version: 2024-02-01

28  
papers

1,056  
citations

759055

12  
h-index

552653

26  
g-index

28  
all docs

28  
docs citations

28  
times ranked

1384  
citing authors

| #  | ARTICLE   | IF    | CITATIONS |
|----|---|-------|-----------|
| 1  | Adjuvant Treatment of Early Ovarian Clear Cell Carcinoma: A Population-Based Study of Whole Abdominal Versus Pelvic Nodal Radiotherapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 172-180.   | 2.3   | 6         |
| 2  | Canadian cost-effectiveness model of BRCA-driven surgical prevention of breast/ovarian cancers compared to treatment if cancer develops. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 104-112.  | 0.2   | 13        |
| 3  | Single or two drug combination therapy as initial treatment for low risk, gestational trophoblastic neoplasia. A Canadian analysis. <i>Gynecologic Oncology</i> , 2020, 157, 367-371.   | 0.6   | 5         |
| 4  | Targeted surgical prevention of epithelial ovarian cancer is cost effective and saves money in BRCA mutation carrying family members of women with epithelial ovarian cancer. A Canadian model. <i>Gynecologic Oncology</i> , 2019, 153, 87-91.                                       | 0.6   | 11        |
| 5  | Chemotherapy is of Value in Second Line and Beyond, Relapsed High-grade, Serous Epithelial Ovarian Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 379-384.  | 0.6   | 3         |
| 6  | Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap. <i>Journal of Medical Genetics</i> , 2018, 55, 571-577.   | 1.5   | 33        |
| 7  | Survival Benefit of Adjuvant Radiotherapy: An Analysis of Low-Stage Invasive Ovarian Mucinous Carcinomas. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1819-1825.   | 1.2   | 4         |
| 8  | Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 493-506. | 157.7 | 58        |
| 9  | Ovarian cancer screening: UKCTOCS trial. <i>Lancet, The</i> , 2016, 387, 2602-2603.   | 6.3   | 4         |
| 10 | Time for a Level Playing Field: Inequalities in Regulatory/Approval Processes—The Example of Bevacizumab in Epithelial Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1539-1542.   | 0.8   | 5         |
| 11 | Early-Stage Endometrioid Ovarian Carcinoma: Population-Based Outcomes in British Columbia. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 1401-1405.  | 1.2   | 18        |
| 12 | Population-based treatment and outcomes of Stage I uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2014, 132, 61-64.  | 0.6   | 19        |
| 13 | Follow-Up of Epithelial Ovarian Cancer: Overdue For A Major Rethink. <i>Current Oncology Reports</i> , 2013, 15, 204-206.   | 1.8   | 1         |
| 14 | Preoperative Radiotherapy for Inoperable Stage II Endometrial Cancer: Insights into Improving Treatment and Outcomes. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2013, 35, 635-639.  | 0.3   | 4         |
| 15 | Low-Stage Ovarian Clear Cell Carcinoma: Population-Based Outcomes in British Columbia, Canada, With Evidence for a Survival Benefit As a Result of Irradiation. <i>Journal of Clinical Oncology</i> , 2012, 30, 1656-1662.  | 0.8   | 109       |
| 16 | Combined methotrexate-dactinomycin: An effective therapy for low-risk gestational trophoblastic neoplasia. <i>Gynecologic Oncology</i> , 2012, 124, 553-557.  | 0.6   | 18        |
| 17 | Which is the better surgical strategy for newly diagnosed epithelial ovarian cancer. <i>Current Opinion in Oncology</i> , 2011, 23, 501-506.  | 1.1   | 7         |
| 18 | Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group. <i>Journal of Clinical Oncology</i> , 2011, 29, 3278-3285.  | 0.8   | 321       |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Triple Cytotoxic Therapy for Advanced Ovarian Cancer: A Failed Application, Not a Failed Strategy. <i>Journal of Clinical Oncology</i> , 2009, 27, 1355-1358.  | 0.8 | 9         |
| 20 | R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines.. <i>Blood</i> , 2009, 114, 408-408.                       | 0.6 | 28        |
| 21 | The Role of Platins in Newly Diagnosed Endometrial Cancer. , 2009, , 307-315.  |     | 0         |
| 22 | Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience. <i>Gynecologic Oncology</i> , 2008, 108, 58-62.                                   | 0.6 | 55        |
| 23 | FDG-PET Guided Consolidative Radiotherapy in Patients with Advanced Stage Hodgkin Lymphoma with Residual Abnormalities on Post Chemotherapy CT Scan.. <i>Blood</i> , 2007, 110, 213-213.   | 0.6 | 3         |
| 24 | Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) Patients with a Negative Pet Scan Following Three Cycles of R-CHOP Can Be Effectively Treated with Abbreviated Chemoimmunotherapy Alone.. <i>Blood</i> , 2007, 110, 787-787. | 0.6 | 16        |
| 25 | Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CHOP-R Can Be Predicted by Stage and Serum Lactate Dehydrogenase (LDH) Level.. <i>Blood</i> , 2006, 108, 2739-2739.                                  | 0.6 | 0         |
| 26 | Identifying patients unlikely to benefit from further chemotherapy: A descriptive study of outcome at each relapse in ovarian cancer. <i>Gynecologic Oncology</i> , 2005, 97, 862-869.   | 0.6 | 20        |
| 27 | Transformed Lymphoma: Incidence and Long-Term Outcome.. <i>Blood</i> , 2004, 104, 3253-3253.   | 0.6 | 3         |
| 28 | Paclitaxel and Carboplatin, Alone or With Irradiation, in Advanced or Recurrent Endometrial Cancer: A Phase II Study. <i>Journal of Clinical Oncology</i> , 2001, 19, 4048-4053.   | 0.8 | 283       |